Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Issues

Volume 22, Issue 6
15 March 2016
Issue Cover
All Issues
  • Cover Image

    Cover Image

    issue cover
    The cover shows a model of pazopanib (light pink carbons) bound to HLA-B*57:01. Abacavir (orange carbons) from the crystal structure of abacavir bound to HLA-B*57:01 (grey carbons) is overlaid for reference. For details, see the article by Xu and colleagues on page 1371 of this issue.
  • PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265

Highlights

Highlights of This Issue
View articletitled, Highlights of This Issue
Open the PDF for in another window

CCR Translations

Bone Disease in Myeloma: The Claws of CRAB
Rafael Fonseca; Tania Jain
View articletitled, Bone Disease in Myeloma: The Claws of CRAB
Open the PDF for in another window
Surgical Guidance in Prostate Cancer: “From Molecule to Man” Translations
Fijs W.B. van Leeuwen; Henk G. van der Poel
View articletitled, Surgical Guidance in Prostate Cancer: “From Molecule to Man” Translations
Open the PDF for in another window

CCR Drug Updates

FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation–Positive Non–Small Cell Lung Cancer
Dickran Kazandjian; Gideon M. Blumenthal; Weishi Yuan; Kun He; Patricia Keegan; Richard Pazdur
View articletitled, FDA Approval of Gefitinib for the Treatment of Patients with Metastatic <em>EGFR</em> Mutation–Positive Non–Small Cell Lung Cancer
Open the PDF for in another window

Molecular Pathways

Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy
Maurizio Scaltriti; Moshe Elkabets; José Baselga
View articletitled, Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy
Open the PDF for in another window

Review

Author Choice
Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example
Jeffrey R. Sachs; Kapil Mayawala; Satvik Gadamsetty; Soonmo Peter Kang; Dinesh P. de Alwis
View articletitled, Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example
Supplementary data
Open the PDF for in another window

Clinical Trial Brief Report

Author Choice
An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib
Christina Danial; Kavita Y. Sarin; Anthony E. Oro; Anne Lynn S. Chang
View articletitled, An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib
Supplementary data
Open the PDF for in another window

Cancer Therapy: Clinical

Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients—Report of a Phase I/IIa Clinical Trial
Amandine Legat; Hélène Maby-El Hajjami; Petra Baumgaertner; Laurène Cagnon; Samia Abed Maillard; Christine Geldhof; Emanuela M. Iancu; Luc Lebon; Philippe Guillaume; Danijel Dojcinovic; Olivier Michielin; Emanuela Romano; Grégoire Berthod; Donata Rimoldi; Frédéric Triebel; Immanuel Luescher; Nathalie Rufer; Daniel E. Speiser
View articletitled, Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients—Report of a Phase I/IIa Clinical Trial
Supplementary data
Open the PDF for in another window
Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib
Emily C. Zabor; Glenn Heller; Lawrence H. Schwartz; Paul B. Chapman
View articletitled, Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAF<sup>V600E</sup>-Mutated Metastatic Melanoma Patients Treated with Vemurafenib
Supplementary data
Open the PDF for in another window
A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors
Kyriakos P. Papadopoulos; Robin Kate Kelley; Anthony W. Tolcher; Albiruni R. Abdul Razak; Katherine Van Loon; Amita Patnaik; Philippe L. Bedard; Ariceli A. Alfaro; Muralidhar Beeram; Lieve Adriaens; Carrie M. Brownstein; Israel Lowy; Ana Kostic; Pamela A. Trail; Bo Gao; A. Thomas DiCioccio; Lillian L. Siu
View articletitled, A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors
Supplementary data
Open the PDF for in another window
Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer
Bruce Montgomery; Mario A. Eisenberger; Matthew B. Rettig; Franklin Chu; Roberto Pili; Joseph J. Stephenson; Nicholas J. Vogelzang; Alan J. Koletsky; Luke T. Nordquist; William J. Edenfield; Khalid Mamlouk; Karen J. Ferrante; Mary-Ellen Taplin
View articletitled, Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer
Supplementary data
Open the PDF for in another window
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
Melinda S. Merchant; Matthew Wright; Kristin Baird; Leonard H. Wexler; Carlos Rodriguez-Galindo; Donna Bernstein; Cindy Delbrook; Maya Lodish; Rachel Bishop; Jedd D. Wolchok; Howard Streicher; Crystal L. Mackall
View articletitled, Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
Supplementary data
Open the PDF for in another window
HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer
Chun-Fang Xu; Toby Johnson; Xiaojing Wang; Chris Carpenter; Alan P. Graves; Liling Warren; Zhengyu Xue; Karen S. King; Dana J. Fraser; Sandy Stinnett; Linda P. Briley; Ionel Mitrica; Colin F. Spraggs; Matthew R. Nelson; Hiroomi Tada; Andreas du Bois; Thomas Powles; Neil Kaplowitz; Lini N. Pandite
View articletitled, <em>HLA-B</em>*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer
Supplementary data
Open the PDF for in another window
Bone Marker–Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study
Noopur Raje; Robert Vescio; Charles W. Montgomery; Ashraf Badros; Nikhil Munshi; Richard Orlowski; Joseph T. Hadala; Ghulam Warsi; Eliza Argonza-Aviles; Solveig G. Ericson; Kenneth C. Anderson
View articletitled, Bone Marker–Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study
Open the PDF for in another window
Author Choice
Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
Masafumi Ikeda; Takuji Okusaka; Shuichi Mitsunaga; Hideki Ueno; Toshiyuki Tamai; Takuya Suzuki; Seiichi Hayato; Tadashi Kadowaki; Kiwamu Okita; Hiromitsu Kumada
View articletitled, Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
Supplementary data
Open the PDF for in another window

Personalized Medicine and Imaging

Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy
Cesar A. Santa-Maria; Consortium on Breast Cancer Pharmacogenomics (COBRA); Amanda Blackford; Consortium on Breast Cancer Pharmacogenomics (COBRA); Anne T. Nguyen; Consortium on Breast Cancer Pharmacogenomics (COBRA); Todd C. Skaar; Consortium on Breast Cancer Pharmacogenomics (COBRA); Santosh Philips; Consortium on Breast Cancer Pharmacogenomics (COBRA); Steffi Oesterreich; Consortium on Breast Cancer Pharmacogenomics (COBRA); James M. Rae; Consortium on Breast Cancer Pharmacogenomics (COBRA); Zeruesenay Desta; Consortium on Breast Cancer Pharmacogenomics (COBRA); Jason Robarge; Consortium on Breast Cancer Pharmacogenomics (COBRA); Norah Lynn Henry; Consortium on Breast Cancer Pharmacogenomics (COBRA); Anna M. Storniolo; Consortium on Breast Cancer Pharmacogenomics (COBRA); Daniel F. Hayes; Consortium on Breast Cancer Pharmacogenomics (COBRA); Roger S. Blumenthal; Consortium on Breast Cancer Pharmacogenomics (COBRA); Pamela Ouyang; Consortium on Breast Cancer Pharmacogenomics (COBRA); Wendy S. Post; Consortium on Breast Cancer Pharmacogenomics (COBRA); David A. Flockhart; Consortium on Breast Cancer Pharmacogenomics (COBRA); Vered Stearns; Consortium on Breast Cancer Pharmacogenomics (COBRA)
View articletitled, Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy
Supplementary data
Open the PDF for in another window
Fluorescent Image–Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time
Geoffrey A. Sonn; Andrew S. Behesnilian; Ziyue Karen Jiang; Kirstin A. Zettlitz; Eric J. Lepin; Laurent A. Bentolila; Scott M. Knowles; Daniel Lawrence; Anna M. Wu; Robert E. Reiter
View articletitled, Fluorescent Image–Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time
Supplementary data
Open the PDF for in another window
Patients with a High Polygenic Risk of Breast Cancer do not have An Increased Risk of Radiotherapy Toxicity
Leila Dorling; Gillian C. Barnett; Kyriaki Michailidou; Charlotte E. Coles; Neil G. Burnet; John Yarnold; Rebecca M. Elliott; Alison M. Dunning; Paul D.P. Pharoah; Catharine M. West
View articletitled, Patients with a High Polygenic Risk of Breast Cancer do not have An Increased Risk of Radiotherapy Toxicity
Supplementary data
Open the PDF for in another window
ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer
Subrata Manna; Josefine Bostner; Yang Sun; Lance D. Miller; Anya Alayev; Naomi S. Schwartz; Elin Lager; Tommy Fornander; Bo Nordenskjöld; Jane J. Yu; Olle Stål; Marina K. Holz
View articletitled, ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer
Supplementary data
Open the PDF for in another window

Cancer Therapy: Preclinical

IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
Zhuonan Zhuang; Huai-Qiang Ju; Mitzi Aguilar; Takashi Gocho; Hao Li; Tomonori Iida; Harold Lee; Xiaoqiang Fan; Haijun Zhou; Jianhua Ling; Zhongkui Li; Jie Fu; Min Wu; Min Li; Davide Melisi; Yoichiro Iwakura; Kesen Xu; Jason B. Fleming; Paul J. Chiao
View articletitled, IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
Supplementary data
Open the PDF for in another window
Author Choice
A Novel Bioavailable BH3 Mimetic Efficiently Inhibits Colon Cancer via Cascade Effects of Mitochondria
Xuefeng Wang; Chen Zhang; Xiangming Yan; Bin Lan; Jianyong Wang; Chongyang Wei; Xingxin Cao; Renxiao Wang; Jianhua Yao; Tao Zhou; Mi Zhou; Qiaoling Liu; Biao Jiang; Pengfei Jiang; Santosh Kesari; Xinjian Lin; Fang Guo
View articletitled, A Novel Bioavailable BH3 Mimetic Efficiently Inhibits Colon Cancer via Cascade Effects of Mitochondria
Supplementary data
Open the PDF for in another window
Combination of Photodynamic Therapy and Specific Immunotherapy Efficiently Eradicates Established Tumors
Jan Willem Kleinovink; Pieter B. van Driel; Thomas J. Snoeks; Natasa Prokopi; Marieke F. Fransen; Luis J. Cruz; Laura Mezzanotte; Alan Chan; Clemens W. Löwik; Ferry Ossendorp
View articletitled, Combination of Photodynamic Therapy and Specific Immunotherapy Efficiently Eradicates Established Tumors
Supplementary data
Open the PDF for in another window
Author Choice
Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation
Jessica A. Couch; Gu Zhang; Joseph C. Beyer; Christina L. Zuch de Zafra; Priyanka Gupta; Amrita V. Kamath; Nicholas Lewin-Koh; Jacqueline Tarrant; Krishna P. Allamneni; Gary Cain; Sharon Yee; Sarajane Ross; Ryan Cook; Siao Ping Tsai; Jane Ruppel; John Brady Ridgway; Maciej Paluch; Philip E. Hass; Jayme Franklin; Minhong Yan
View articletitled, Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation
Supplementary data
Open the PDF for in another window

Biology of Human Tumors

Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia
Stéphanie Poulain; Christophe Roumier; Aurélie Venet-Caillault; Martin Figeac; Charles Herbaux; Guillemette Marot; Emmanuelle Doye; Elisabeth Bertrand; Sandrine Geffroy; Frédéric Lepretre; Olivier Nibourel; Audrey Decambron; Eileen Mary Boyle; Aline Renneville; Sabine Tricot; Agnès Daudignon; Bruno Quesnel; Patrick Duthilleul; Claude Preudhomme; Xavier Leleu
View articletitled, Genomic Landscape of <em>CXCR4</em> Mutations in Waldenström Macroglobulinemia
Supplementary data
Open the PDF for in another window
Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer
Nadine J. McCleary; Kaori Sato; Reiko Nishihara; Kentaro Inamura; Teppei Morikawa; Xuehong Zhang; Kana Wu; Mai Yamauchi; Sun A. Kim; Yasutaka Sukawa; Kosuke Mima; Zhi Rong Qian; Charles S. Fuchs; Shuji Ogino; Jeffrey A. Meyerhardt
View articletitled, Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer
Supplementary data
Open the PDF for in another window
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Sherene Loi; Sathana Dushyanthen; Paul A. Beavis; Roberto Salgado; Carsten Denkert; Peter Savas; Susan Combs; David L. Rimm; Jennifer M. Giltnane; Monica V. Estrada; Violeta Sánchez; Melinda E. Sanders; Rebecca S. Cook; Mark A. Pilkinton; Simon A. Mallal; Kai Wang; Vincent A. Miller; Phil J. Stephens; Roman Yelensky; Franco D. Doimi; Henry Gómez; Sergey V. Ryzhov; Phillip K. Darcy; Carlos L. Arteaga; Justin M. Balko
View articletitled, RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Supplementary data
Open the PDF for in another window
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer
Himisha Beltran; Adam Jendrisak; Mark Landers; Juan Miguel Mosquera; Myriam Kossai; Jessica Louw; Rachel Krupa; Ryon P. Graf; Nicole A. Schreiber; David M. Nanus; Scott T. Tagawa; Dena Marrinucci; Ryan Dittamore; Howard I. Scher
View articletitled, The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer
Supplementary data
Open the PDF for in another window
Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers
Ana M. Aparicio; Li Shen; Elsa Li Ning Tapia; Jing-Fang Lu; Hsiang-Chun Chen; Jiexin Zhang; Guanglin Wu; Xuemei Wang; Patricia Troncoso; Paul Corn; Timothy C. Thompson; Bradley Broom; Keith Baggerly; Sankar N. Maity; Christopher J. Logothetis
View articletitled, Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers
Supplementary data
Open the PDF for in another window
Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling
Tao Wang; Wen Song; Yuan Chen; Ruibao Chen; Zhuo Liu; Licheng Wu; Mingchao Li; Jun Yang; Liang Wang; Jihong Liu; Zhangqun Ye; Chenguang Wang; Ke Chen
View articletitled, Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling
Supplementary data
Open the PDF for in another window

Advertisement

Latest News
Cancer Grand Challenges Throws Down Gauntlet
Aspirin Boosts Immune Response to Stop Cancer Spread
Clinicians Warn Trump’s EOs Will Harm LGBTQ+ Patients
View more recent articles
Breaking
DFCI Wins Approval for $1.7 Billion Hospital
Roche Inks Deal Worth up to $1 Billion Over ADCs
AstraZeneca to Buy Lentivirus-Focused Biotech
View more recent articles
Research Watch
Synonymous Mutations in m6A-modified Sites Can Destabilize Tumor Suppressors
MIF–ACKR3 Signaling Drives Cancer Cachexia by Impairing Adipogenesis
Epithelial-to-Mesenchymal Transition Supports Pancreatic Cancer Evolution
View more recent articles

NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck.  None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.

  • Online ISSN 1557-3265
  • Print ISSN 1078-0432

AACR Journals

 

 

  • Copyright © 2025 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept